Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 0.8% - Time to Sell?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) fell 0.8% on Thursday . The stock traded as low as $3.89 and last traded at $3.94. 9,469 shares traded hands during mid-day trading, a decline of 28% from the average session volume of 13,195 shares. The stock had previously closed at $3.97.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on shares of Eupraxia Pharmaceuticals in a report on Friday, February 21st. They issued a "buy" rating and a $12.00 price objective on the stock.

Eupraxia Pharmaceuticals Stock Up 0.8%

The firm's 50 day simple moving average is $3.67 and its 200 day simple moving average is $3.48. The company has a market cap of $142.32 million, a price-to-earnings ratio of -5.51 and a beta of 0.65.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EPRX. Bank of Montreal Can raised its position in shares of Eupraxia Pharmaceuticals by 15.2% during the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after buying an additional 7,500 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $31,000. Raymond James Financial Inc. acquired a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $37,000. Royal Bank of Canada increased its stake in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock valued at $1,125,000 after acquiring an additional 59,683 shares during the period. Finally, Scotia Capital Inc. increased its stake in shares of Eupraxia Pharmaceuticals by 11.6% during the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock valued at $5,072,000 after acquiring an additional 160,960 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.